BioNTech’s quarterly profit soars on COVID-19 vaccine demand

KIFI

Published March 30, 2022 6:03 AM

BERLIN (AP) — BioNTech has reported another quarter of strong earnings growth. The German pharmaceutical company teamed with Pfizer to develop the first widely used COVID-19 vaccine. The company on Wednesday posted net profit of 3.2 billion euros for the final three months of 2021. That’s up from 367 million euros in the same period the previous year. Earnings per share rose to 12.18 euros from 1.43 euros a year ago. Heavy demand for the vaccine also helped Pfizer report healthy quarterly earnings last month. Vaccinations with the Pfizer-BioNTech vaccine started in December 2020. BioNTech said about 2.6 billion doses of the vaccine had been delivered last year.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.